

Title: Prevalence and determinants of cervicovaginal, oral, and anal HPV infection in a population of transgender and gender diverse people assigned female at birth

Authors: Ryan D. McIntosh¹, Emily C. Andrus¹, Heather M. Walline², Claire B. Sandler¹, Christine M. Goudsmit², Molly B. Moravek³, Daphna Stroumsa³, Shanna K. Kattari^{4,5}, Andrew F. Brouwer^{1,*}

Affiliations:

1. Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States
2. Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States
3. Reproductive Endocrinology Clinic, Center for Reproductive Medicine, University of Michigan, Ann Arbor, MI, United States
4. School of Social Work, University of Michigan, Ann Arbor, MI, United States
5. Department of Women's and Gender Studies, University of Michigan, Ann Arbor, MI, United States

Corresponding author*: email: brouweaf@umich.edu; mail: Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI, 48109, United States

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Abstract

Introduction: HPV causes oral, cervicovaginal, and anogenital cancer, and cervical cancer screening options include HPV testing of a physician-collected sample. Transgender and gender diverse (TGD) people assigned female at birth (AFAB) face discrimination and stigma in many healthcare settings; are believed to be a lower risk for cervical cancer by many physicians; are less likely to be up to date on preventive health care services such as pelvic health exams; and are more likely to have inadequate results from screening tests. Self-sampling options may increase access and participation in HPV testing and cancer screening.

Methods: We recruited 137 TGD individuals AFAB for an observational study, mailing them a kit to self-collect cervicovaginal, oral, and anal samples at home. We tested samples for HPV genotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 90 using a PCR mass array test.

Results: 102 participants completed the study. Among those with valid tests, 8.8% were positive for oral HPV, 30.5% were positive for cervicovaginal HPV, and 39.6% were positive for anal HPV. A large fraction of anal (50.0%) and oral (71.4%) infections were concordant with a cervicovaginal infection of the same type.

Conclusions: HPV infection in TGD people AFAB may be just as high, if not higher, than in cisgender women. It is essential that we reduce barriers to cancer screening for TGD populations, such as through the development of a clinically approved self-screening HPV test.

Keywords: HPV, transgender, gender diverse, cervicovaginal, anal, oral, self-sampling

23 Introduction

24 The human papillomavirus (HPV) causes more than 24,000 cancers each year in women and
25 people assigned female at birth (AFAB), including 12,000 cervical cancers [1]. The U.S.
26 Preventive Services Task Force (USPSTF) recently revised cervical cancer screening guidelines
27 to include the option of testing for high-risk HPV instead of, or in addition to, cytological (Pap)
28 screening [2]. Many physicians believe transmasculine people (those who were AFAB but who
29 identify as male or masculine [3]) and nonbinary and gender diverse people (those who identify
30 between or beyond the male–female gender binary; note that transgender and gender diverse
31 may be overlapping identities) to be at a lower risk for cervical cancer than cisgender (i.e., non-
32 transgender) women because of lower rates of penile–vaginal intercourse [4]. However, prior
33 studies have suggested that transmasculine populations have just as high or higher rates of

34 sexually transmitted infections and may be at equal or higher risk of HPV-associated cancers [3,
35 5]. Moreover, transgender and gender diverse (TGD) people face discrimination and stigma in
36 health care settings and daily life and consequently are less likely to seek reproductive and
37 preventive health care services, including cervical cancer screening [6–12]. Recent studies have
38 proposed HPV self-sampling as an alternative to provider-based testing, circumventing some of
39 these known barriers to screening [13–16]. However, any clinically approved self-sampling
40 protocol should be designed to address the specific physical and mental discomfort that TGD
41 people may face. Ultimately, more work is needed to understand the risk of HPV-associated
42 cancers in TGD populations [17] as well as the impact and feasibility of HPV self-sampling as a
43 cervical cancer screening tool. This work is especially crucial in the context of the updated
44 USPSTF guidelines and the current politicization of TGD medical care.

45 While HPV is best known as the etiological agent of nearly every cervical cancer, it also causes
46 over 90% of anal cancers, 40% of vaginal, vulvar, and penile cancers, and more than 60% of
47 oropharyngeal and other oral cancers [1, 18, 19]. Oropharyngeal cancer is now the HPV-
48 associated cancer with the highest incidence in the U.S., with approximately 19,000 of the
49 43,000 HPV-associated cancers diagnosed occurring at oropharyngeal sites (approximately
50 12,000 are cervical, 7,000 are anal, and the rest are at other genital sites) [20]. There is
51 increasing recognition that HPV must be considered a multisite (cervicovaginal, oral, anal)
52 infection to fully understand its epidemiology [21–26]. We extend this multisite perspective to
53 HPV-associated cancer risk, screening, and prevention for TGD people AFAB. Specifically, we
54 enrolled a sample of TGD AFAB people and mailed them at-home, self-sampling kits, which we
55 tested for cervicovaginal, oral, and anal HPV.

56 **Methods**

57 **Ethics statement**

58 This study was approved by the University of Michigan Institutional Review Board (IRBMED:
59 HUM00166980) and Rogel Cancer Center Protocol Review Committee. Prior to beginning the
60 study, ten TGD community consultants reviewed and commented on the study protocol,
61 surveys, and sample collection instructions; each person was compensated with a \$100 gift card
62 for their time. In the main study, all participants gave written, informed consent virtually, using
63 the SignNow platform. Participants were compensated with a \$50 gift card for full study
64 completion and were returned the results of their high-risk HPV test, with appropriate cautions
65 given the non-clinical sampling. This study included the use of a cervicovaginal swab outside of

66 the Food and Drug Administration (FDA) approved context (i.e., used by the participant, not by a
67 physician, to collect a sampling for HPV testing); the FDA determined the study, including return
68 of qualified research results to participants, to be a non-significant risk device study.

69 **Study population**

70 **Eligibility criteria**

71 To participate in the study, potential candidates had to meet all of the following criteria: (1) be
72 between the ages of 21–65, (2) have been assigned female at birth (AFAB), (3) have a male,
73 masculine, nonbinary, queer, or another gender diverse identity other than female or feminine,
74 (4) not be pregnant, (5) not have had cervix removed, (6) not be menstruating on the day of the
75 cervicovaginal swab self-collection, and (7) live in Michigan, Illinois, Indiana, Ohio, or Wisconsin.
76 Individuals of any HPV vaccination status or prior HPV infection status were eligible.

77 **Recruitment and enrollment**

78 Recruitment methods included advertisements and listserv emails through Michigan Medicine's
79 Comprehensive Gender Services Program, the University of Michigan Health Research posting
80 site, social media posts, outreach to statewide LGBTQ+ groups and organizations, and word of
81 mouth referrals. Interested participants reached out to study staff, who screened them for
82 eligibility requirements. Potential participants were then invited to an individual virtual video call
83 to review the consent form and details of the study.

84 **Surveys**

85 Participants completed two surveys on an online platform (Qualtrics). The demographic and
86 behavioral survey include questions on sociodemographic characteristics; healthcare utilization;
87 sexual behavior and history; and substance use. The self-sampling survey, which was
88 administered after specimen collection, included questions on the acceptability, comfort, and
89 ease-of-use of the cervicovaginal and anal self-sampling protocols, as well as preference for
90 self- or physician-administered testing/screening.

91 **Biospecimen collection and processing**

92 Participants were mailed a study test kit that included materials and instructions for self-
93 collection of 3 separate biospecimens: a cervicovaginal swab, an oral rinse, and an anal swab.
94 Self-sampling instructions were modified to remove gendered language (e.g., “genital swab” or
95 “front hole swab” instead of “cervicovaginal swab” or “Evalyn Brush”). All samples were

96 repackaged in USPS biospecimen compliant packaging then returned via mail to the study. The
97 estimated time lapse between sample collection and package receipt was 5 days.

98 **Cervicovaginal swab:** Participants used an Evalyn Brush (Rovers Medical Devices BV, Oss,
99 Netherlands) to self-collect a cervicovaginal sample [27]. Participants were provided with self-
100 collection instructions that were modified from the original, with permission from Rovers Medical
101 Devices, to remove gendered language. In short, participants were instructed to use the plunger
102 on the device to insert the brush into their vagina to the appropriate depth, rotate the brush 5
103 times, and then retract and cap the device for transport. HPV DNA on a dry-stored Evalyn Brush
104 has previously been shown to be analytically stable [28]. Upon return to the study, the protective
105 cap was removed, and the brush tip was vigorously agitated then gently mashed in a 20mL vial
106 of PreservCyt solution (Hologic, Inc.; Marlborough, MA). Since the genital mucus sample often
107 dried during transport, the brush bristles arrived firmly adhered together. Mashing ensured
108 complete separation of the plastic brush bristles, which improved elution of the cells from the
109 brush into the PreservCyt media. The tip of the brush was then removed from the barrel of the
110 device using a set of autoclaved disposable forceps provided by the manufacturer and left to
111 soak for a minimum of 5 minutes to rehydrate dried mucus that would have otherwise impeded
112 cell elution. The device barrel was discarded, but the brush tip was retained within each
113 PreservCyt vial. After resting, each vial was vortexed for 30 seconds to remove cervical cells
114 that were adhered to the brush bristles. A 10mL aliquot was pipetted into a conical tube and
115 sent to our research laboratory for genotyping, a 2mL aliquot was pipetted into a 5mL transport
116 tube and sent to Michigan Medicine Pathology for Cobas testing. Samples were stored at 0°C.

117 **Anal swab:** Participants were sent a Dacron flocked swab (Puritan Medical Products; Guilford,
118 ME), a 10ml conical tube with 1 mL of DNA/RNA Shield (Zymo Research; Irvine, CA) or
119 Preserv-Cyt. Sample collection instructions were based on those developed by Meites et al.
120 [29]; briefly, participants were instructed to insert the swab 2 inches into anus, twirl the swab
121 between the thumb and forefinger while pressing laterally against the anal walls, and then
122 remove the swab from the body. The swab was then placed in the corresponding conical tube.
123 Upon return to the study, the conical tube containing the Dacron flocked swab and transport
124 media were vortexed for 15 seconds to release cells from the fibers of the swab tip. The swab
125 was then extracted from the tube with a pair of sanitized hemostats and discarded. The sample
126 was sent to our research laboratory for genotyping.

127 **Oral rinse:** Participants received 1 50 mL conical tube with 10 mL Scope Mouthwash (Proctor &
128 Gamble; Cincinnati, OH). Participants were instructed to swish the mouth wash vigorously for 30

129 seconds, then spit the contents back into the original 50 mL tube. Upon return to the study,
130 samples were transferred to our research laboratory for genotyping.

131 **HPV testing**

132 **High-risk HPV testing:** Cervicovaginal samples were tested by Michigan Medicine Pathology
133 clinical laboratories using a Cobas high-risk HPV test (Roche Molecular Systems, Inc;
134 Branchburg, NJ), a polymerase chain reaction (PCR)-based test that provides pooled results on
135 high-risk genotypes and individual results for HPV-16 and HPV-18, the highest-risk genotypes.
136 The results of this test were returned to participants.

137 **PCR Mass Array HPV genotyping:** Cervicovaginal, anal, and oral samples were tested for
138 HPV genotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 90. Sample
139 processing and DNA extraction details are the same as in Eisenberg et al. [30], and technical
140 details of the PCR Mass Array test are given in Walline et al. [31]. Participants whose samples
141 contained insufficient DNA or otherwise resulted in inconclusive test results were denoted as
142 invalid. The results of the PCR Mass Array were not returned to participants.

143 **Results**

144 **Demographics, behaviors, and medical history**

145 We enrolled 137 participants between August 2020 and August 2021, and 102 participants
146 completed the biospecimen collection and demographic and behavior questionnaire. The
147 demographic, behavioral, and medical history characteristics of these participants are
148 summarized in Table 1; a table summarizing participants' numbers of recent sexual partners is
149 given in the supporting information (Table S1). While participants ranged from 21 to 59 years of
150 age, the majority of those who completed the study (66%) were under 30 years old. The study
151 participants were predominantly White (82%). Participants were also highly educated, with 92%
152 reporting attending at least some college and 65% having a 2-year, 4-year, or
153 professional/doctorate degree. Reported annual income was distributed fairly evenly between
154 the categories ranging from less than \$10,000 to at least \$50,000. Most participants reported
155 having a single partner, either married/partnered (46%) or not (12%); about 25% of participants
156 were never married or partnered.

157 Approximately half (48%) of participants identified as nonbinary, genderfluid, or agender and
158 half (49%) as transgender male, transmasculine, or male (note that people who identify as male
159 and were AFAB may or may not include being transgender as part of their gender identity). Most

160 participants identified their sexual orientation as bisexual, pansexual, and omnisexual (43%) or
161 simply as queer (36%). The vast majorities of participants reported a history of deep kissing
162 (96%), mutual masturbation (89%), vaginal/front hole sex (98%), and oral sex (99%), while 60%
163 reported ever engaging in anal sex, and 43% having ever engaged in anilingus/rimming. When
164 asked about partners within the last 6 months, participants overall reported similar numbers of
165 partners with a vagina and partners with a penis for vaginal, anal, or oral sex. A table of recent
166 (past 6 month) sexual activity by sex type and partner genitals is given in the Supporting
167 Information (Table S1).

168 About 75% of participants responded that they have transitioned or are currently transitioning
169 from living as the gender assigned at birth, 76% of whom reported ever taking hormones as a
170 part of gender-affirming medical care. Only 42% of transitioned or transitioning participants
171 reported gender-affirming surgery. The vast majority (86%) of participants reported never being
172 pregnant. Most participants indicated currently using alcohol (75%) and marijuana (54%), while
173 only 32% reported ever smoking cigarettes. More than half (57%) reported receiving at least one
174 dose of a vaccination against HPV, and most (81%) reported having ever had a cervical pap
175 smear. While none of the participants reported being uninsured, 81% reported delaying regular
176 medical checkups. Most of these (59%) were due to fear of physical discomfort or dysphoria.
177 Most participants (53%) also reported delaying care for acute medical needs, with 36% of
178 participants reporting delaying acute treatment due to concerns for physical discomfort or
179 dysphoria.

180 **HPV prevalence and determinants**

181 HPV prevalence varied across oral, cervicovaginal, and anal sites and across demographic and
182 behavioral characteristics (Table 2). HPV was detected in 8.8% of valid tests on oral samples,
183 30.5% of valid tests on cervicovaginal samples, and 39.6% of valid tests on anal samples. High-
184 risk HPV, which includes genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, was
185 detected in 6.6% of oral, 26.8% of cervicovaginal, and 27.1% of anal samples. The genotype-
186 specific HPV prevalence by site is given in the Supporting Information (Table S2).

187 Of the 44 participants with both valid cervicovaginal and anal test results, 25.0% of pairs of anal
188 and cervicovaginal test results detected the presence of HPV of the same genotype. These
189 concordant infections represented 34.4% of cervicovaginal infections in this group and 50.0% of
190 anal infections. Of the 75 participants with valid results for both oral and cervicovaginal tests,
191 6.7% of pairs of oral and cervicovaginal tests detected the presence of the same genotype of
192 HPV. These concordant infections represented only 12.2% of cervicovaginal infections in this

193 group but 71.4% of oral infections. The HPV genotype-specific concordance for
194 anal/cervicovaginal and oral/ cervicovaginal samples in the supporting information (Table S3).

195 No statistically significant associations were found between any characteristic and oral HPV
196 infection. Cervicovaginal HPV infection was statistically significantly associated with the number
197 of deep kissing partners with a penis in the past 6 months (PR 3.12 (95% CI: 1.56, 6.23) for 5+
198 partners vs 0 partners), number of partners with a vagina from whom the participant received
199 oral sex (PR 3.47 (95% CI: 1.52, 7.93) for 2-4 partners vs 0 partners), a history of HPV (PR 2.68
200 (95%CI 1.47, 4.88)), and a history of other STI (PR 2.07 (95%CI 1.11, 3.85)). Anal HPV
201 infection was statistically significantly associated with sexual attraction identity (PR 1.94 (95%
202 CI: 1.06, 3.58) for identifying as homosexual vs bisexual, pansexual, or omnisexual), number of
203 deep kissing partners with a penis in the past 6 months (PR 6.00 (95% CI: 1.54, 2.34) for 5+
204 partners vs 0 partners), and a history of other STI (PR 2.67 (95%CI 1.33, 5.36)).

205 **Discussion**

206 We evaluated the prevalence of cervicovaginal, oral, and anal HPV in a Midwestern TGD AFAB
207 population and investigated the potential association of infection with demographics, health
208 factors, and sexual behaviors. We found HPV prevalence of 8.8% in oral samples, 30.5% in
209 cervicovaginal samples, and 39.6% in anal samples. In a partner study using similar protocols
210 for oral and cervicovaginal HPV detection in a general population with a similar age profile,
211 10.5% of cisgender women (and 9.0% of cisgender men) in the sample were positive for oral
212 HPV, and 20% of cisgender women were positive for cervicovaginal HPV [32] (anal swabs were
213 not collected in the partner study). This comparison suggests that the TGD AFAB population
214 may have higher cervicovaginal HPV prevalence than but similar oral HPV prevalence to the
215 cisgender women. A separate study in a TGD AFAB population, found 16% high-risk HPV
216 prevalence in physician-collected cervicovaginal swabs, compared to the 26.8% high-risk HPV
217 prevalence in our study [13]. Overall, we found no evidence that TGD people AFAB are at a
218 lower risk for HPV and HPV-related cancers, and it is therefore important that screening for
219 cervicovaginal HPV is accessible through affirming medical providers, or, potentially, at-home
220 self-screening.

221 We found a high prevalence of anal HPV among valid tests (39.6%). A meta-analysis of anal
222 HPV prevalence in cisgender women found that cisgender women without HPV-associated
223 cervical pathology had anal HPV prevalence ranging from 4–22%, and prevalence in those with
224 HPV-related cervical pathology ranged from 23–36% [33]. It is concerning, however, that despite
225 modeling our anal sample collection instructions off an established protocol [29], we had low

226 sample validity (that is, low detection of human control indicators) in our anal samples (47%
227 valid). Validity was much higher among oral (89% valid) and cervicovaginal (80% valid)
228 samples. Future work could involve instructional videos demonstrating anal (and cervicovaginal)
229 sample collection techniques, and future work should consider whether there are particular
230 challenges for anal sampling for TGD individuals. A follow-up study will also examine
231 participants' experiences with the cervicovaginal and anal sample self-collection.

232 We found significant differences in HPV prevalence across several participant characteristics
233 and reported behavior. History of an STI diagnosis, likely a proxy for other behavior, was also
234 associated with HPV at both cervicovaginal (PR: 2.07, 95%CI: 1.11, 3.85) and anal (PR: 2.67,
235 95%CI: 1.33, 5.36) sites. HPV is thought to be largely transmitted through sexual activity, and
236 many previous studies have demonstrated associations in general populations [34–41]. Few
237 associations rose to the level of statistical significance, with the exception of the number of deep
238 kissing partners with a penis for both cervicovaginal and anal HPV infection and the number of
239 partners with a vagina that a participant received oral sex from for cervicovaginal HPV infection.
240 More broadly, in many sexual behavior categories, prevalence generally increased with the
241 number of recent sexual partners, even if not statistically significantly. Additionally, although the
242 effects were not statistically significant, there were indications that HPV prevalence among the
243 participants identifying as male, transgender male, or transmasculine was higher than those
244 identifying as nonbinary, genderfluid or agender. There were no significant differences in HPV
245 prevalence by transition status, use of gender affirming hormones, or gender-affirming surgery.

246 We found a high degree of cervicovaginal–anal concordance among the participants with valid
247 results for both anal and cervicovaginal tests. The high concordance of cervicovaginal–anal
248 infection highlights the need to treat HPV as a multisite infection. One limitation is that we
249 cannot tell from our data whether this correlation is the result of autoinoculation from site to site
250 or separate transmission events from the same partner to different sites. In future work, the
251 autoinoculation vs transmission explanations could be further evaluated using gene sequencing
252 and mapping of samples from participants, or by utilizing contact tracing and partner testing. We
253 found many oral infections were genotype concordant with cervicovaginal infections (71%), but
254 few cervicovaginal infections were concordant with an oral infection (12%). These results are
255 consistent with patterns of oral-cervicovaginal concordance in the National Health and Nutrition
256 Examination Survey (NHANES) [42]. Together, our results are consistent with cervicovaginal
257 infections being the source of anal and oral infections.

258 One strength of our study is the multisite design, incorporating oral, cervicovaginal, and anal
259 self-sampling and HPV testing. Additionally, because many gender minority studies in the US
260 are focused on urban, coastal populations, this Midwestern cohort helps to bring context and
261 enhance the generalizability of gender minority studies. We also explicitly included nonbinary
262 and gender diverse participants in this study, who are often overlooked in gender minority
263 research. One limitation of our study is the small sample size, limiting statistical power, although
264 other comparable studies have also had limited sample sizes [13]. Additionally, lack of racial and
265 ethnic diversity in this pilot study is a strong limitation, as there may be important intersectional
266 effects for TGD people of color. Indeed, we found high HPV prevalence among the non-White
267 participants in this study. Future work should use targeted recruitment strategies to achieve
268 better racial and ethnic representation. Finally, while the age distribution of the cohort (66%
269 aged <30 years) is not inherently a limitation, it should be accounted for when try to generalize
270 the results, since HPV prevalence varies by age [42].

271 **Conclusion**

272 In our multisite (cervicovaginal, oral, anal) HPV sampling study in TGD people AFAB, we found
273 HPV oral prevalence consistent with cisgender populations but higher cervicovaginal and anal
274 infection. Our work suggests that the risk of HPV-related cancers in TGD people AFAB may be
275 just as high, if not higher, than in cisgender women. It is essential that we reduce barriers to
276 cancer screening for TGD populations, such as through the development of a clinically approved
277 self-screening HPV test.

278 **Funding**

279 This work was supported by the University of Michigan Rogel Cancer Center (NIH grant
280 P30CA046592). Social media recruitment and data management was supported by the Michigan
281 Institute for Clinical & Health Research (CTSA grant UL1TR002240).

282 **Acknowledgments**

283 We acknowledge our community consultants and our participants, without whom this work would
284 not have been possible.

285 **Competing interests**

286 All authors declare that they have no competing interests.

287

289 References

- 290 [1] Center for Disease Control and Prevention. Fact Sheet: United States Cancer Statistics Data Brief, Cancers
291 Associated with Human Papillomavirus, United States, 2011 to 2015. USCS Data Brief. 2018;4.
- 292 [2] Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Cervical Cancer.
293 JAMA. 2018;320(7):674.
- 294 [3] Reisner SL, Murchison GR. A global research synthesis of HIV and STI biobehavioural risks in female-to-male
295 transgender adults. *Global Public Health*. 2016;11(7-8):866-87.
- 296 [4] Agenor M, Peitzmeier SM, Bernstein IM, McDowell M, Alizaga NM, Reisner SL, et al. Perceptions of cervical
297 cancer risk and screening among transmasculine individuals: patient and provider perspectives. *Culture, Health
298 & Sexuality*. 2016;18(10):1192-206.
- 299 [5] Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of
300 unsatisfactory paps compared to non-transgender females: Implications for cervical cancer screening. *Journal
301 of General Internal Medicine*. 2014;29(5):778-84.
- 302 [6] Gatos KC. A Literature Review of Cervical Cancer Screening in Transgender Men. *Nursing for Women's Health*.
303 2018;22(1):52-62.
- 304 [7] Obedin-Maliver J, de Haan G. Gynecologic Care for Transgender Adults. *Current Obstetrics and Gynecology
305 Reports*. 2017;6(2):140-8.
- 306 [8] Seay J, Ranck A, Weiss R, Salgado C, Fein L, Kobetz E. Understanding Transgender Men's Experiences with
307 and Preferences for Cervical Cancer Screening: A Rapid Assessment Survey. *LGBT Health*. 2017;4(4):304-9.
- 308 [9] Potter J, Peitzmeier SM, Bernstein I, Reisner SL, Alizaga NM, Agenor M, et al. Cervical Cancer Screening for
309 Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians. *Journal of General
310 Internal Medicine*. 2015;30(12):1857-64.
- 311 [10] Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than
312 nontransgender women. *American Journal of Preventive Medicine*. 2014;47(6):808-12.
- 313 [11] Dhillon N, Oliffe JL, Kelly MT, Krist J. Bridging barriers to cervical cancer screening in transgender men: a
314 scoping review. *American journal of men's health*. 2020;14(3):1557988320925691.
- 315 [12] Kattari SK, Gross EB, Harner V, Andrus E, Stroumsa D, Moravek MB, et al. "Doing It on My Own Terms":
316 Transgender and Nonbinary Adults' Experiences with HPV Self-Swabbing Home Testing Kits. *Women's
317 Reproductive Health*. 2022:1-17.
- 318 [13] Reisner SL, Deutsch MB, Peitzmeier SM, White Hughto JM, Cavanaugh TP, Pardee DJ, et al. Test
319 performance and acceptability of self-versus provider-collected swabs for high-risk HPV DNA testing in female-
320 to-male trans masculine patients. *PLoS ONE*. 2018;13(3):1-21.
- 321 [14] Reisner SL, Deutsch MB, Peitzmeier SM, White Hughto JM, Cavanaugh T, Pardee DJ, et al. Comparing self-
322 and provider-collected swabbing for HPV DNA testing in female-to-male transgender adult patients: A mixed-
323 methods biobehavioral study protocol. *BMC Infectious Diseases*. 2017;17(1):1-10.

- 324 [15] McDowell M, Pardee DJ, Peitzmeier S, Reisner SL, Ag´enor M, Alizaga N, et al. Cervical Cancer Screening
325 Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs
326 Versus Provider-Administered Pap Tests. *LGBT Health*. 2017;4(4):252-9.
- 327 [16] Maza M, Mel´endez M, Herrera A, Hernandez X, Rodr´ıguez B, Soler M, et al. Cervical cancer screening with
328 human papillomavirus self-sampling among transgender men in El Salvador. *LGBT health*. 2020;7(4):174-81.
- 329 [17] Brown B, Poteat T, Marg L, Galea JT. Human Papillomavirus-Related Cancer Surveillance, Prevention, and
330 Screening among Transgender Men and Women: Neglected Populations at High Risk. *LGBT Health*.
331 2017;4(5):315-9.
- 332 [18] Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the
333 Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated
334 Cancers and HPV Vaccination Coverage Levels. *Journal of the National Cancer Institute*. 2013;105(3):175-201.
- 335 [19] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*. 2018;68(1):7-30.
- 336 [20] Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human
337 Papillomavirus–Associated Cancers — United States, 1999–2015. *Morbidity and Mortality Weekly Report*.
338 2018;67(33):918-24.
- 339 [21] Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong ZyY, et al. Prevalence of Cervical and Oral
340 Human Papillomavirus Infections Among US Women. *The Journal of Infectious Diseases*. 2014;209(11):1739-
341 43.
- 342 [22] Brouwer AF, Eisenberg MC, Carey TE, Meza R. Trends in HPV cervical and seroprevalence and associations
343 between oral and genital infection and serum antibodies in NHANES 2003-2012. *BMC Infectious Diseases*.
344 2015;15(1):575.
- 345 [23] Kedarisetty S, Orosco RK, Hecht AS, Chang DC, Weissbrod PA, Coffey CS. Concordant Oral and Vaginal
346 Human Papillomavirus Infection in the United States. *JAMA Otolaryngology–Head & Neck Surgery*.
347 2016;8895:1-9.
- 348 [24] Brouwer AF, Meza R, Eisenberg MC. Transmission heterogeneity and autoinoculation in a multisite infection
349 model of HPV. *Mathematical Biosciences*. 2015;270:115-25.
- 350 [25] Patel EU, Rositch AF, Gravitt PE, Tobian AAR. Concordance of Penile and Oral Human Papillomavirus
351 Infections Among Men in the United States. *The Journal of Infectious Diseases*. 2017;215(8):1207-11.
- 352 [26] Sonawane K, Suk R, Chiao EY, Chhatwal J, Qiu P, Wilkin T, et al. Oral human papillomavirus infection:
353 Differences in prevalence between sexes and concordance with genital human papillomavirus infection,
354 NHANES 2011 to 2014. *Annals of Internal Medicine*. 2017;167(10):714-24.
- 355 [27] Rovers Medical Devices. Evalyn@Brush; 2022. [https://www.roversmedicaldevices.com/cell-](https://www.roversmedicaldevices.com/cell-samplingdevices/evalyn-brush/)
356 [samplingdevices/evalyn-brush/](https://www.roversmedicaldevices.com/cell-samplingdevices/evalyn-brush/). Accessed February 5, 2022.
- 357 [28] Ejegod DM, Pedersen H, Alzua GP, Pedersen C, Bonde J. Time and temperature dependent analytical stability
358 of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening. *Papillomavirus Research*.
359 2018;5:192200.

- 360 [29] Meites E, Gorbach PM, Gratz B, Panicker G, Steinau M, Collins T, et al. Monitoring for human papillomavirus
361 vaccine impact among gay, bisexual, and other men who have sex with men—United States, 2012–2014. The
362 Journal of infectious diseases. 2016;214(5):689-96.
- 363 [30] Eisenberg MC, Campredon LP, Brouwer AF, Walline HM, Marinelli BM, Lau YK, et al. Dynamics and
364 Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. *BMJ Open*.
365 2018;8(10):e021618.
- 366 [31] Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus
367 detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. *JAMA*
368 *Otolaryngology–Head & Neck Surgery*. 2013;139(12):1320-7.
- 369 [32] Brouwer AF, Campredon LP, Walline HM, Marinelli BM, Goudsmit CM, Thomas TB, et al. Prevalence and
370 determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and
371 Oropharyngeal Cancer (MHOC) cohort study. *Plos one*. 2022;17(5):e0268104.
- 372 [33] Stier EA, Sebring MC, Mendez AE, Ba FS, Trimble DD, Chiao EY. Prevalence of anal human papillomavirus
373 infection and anal HPV-related disorders in women: a systematic review. *American journal of obstetrics and*
374 *gynecology*. 2015;213(3):278-309.
- 375 [34] Cook RL, Thompson EL, Kelso NE, Friary J, Hosford J, Barkley P, et al. Sexual behaviors and other risk factors
376 for oral human papillomavirus infections in young women. *Sexually Transmitted Diseases*. 2014;41(8):486.
- 377 [35] Pickard RK, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and incidence of oral human
378 papillomavirus infection among young men and women, aged 18-30 years. *Sexually Transmitted Diseases*.
379 2012:559-66.
- 380 [36] Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation.
381 *Journal of Leukocyte Biology*. 2003;74(4):486-96.
- 382 [37] Brouwer AF, Campredon LP, Walline HM, Marinelli BM, Goudsmit CM, Thomas TB, et al. Incidence and
383 clearance of oral and cervicogenital HPV infection: longitudinal analysis of the MHOC cohort study. *BMJ Open*.
384 2022;12(1):e056502.
- 385 [38] Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Rates and determinants of oral
386 human papillomavirus (HPV) infection in young men. *Sexually Transmitted Diseases*. 2012;39(11):860.
- 387 [39] D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and
388 race explain observed differences in prevalence of oral human papillomavirus infection. *PloS one*.
389 2014;9(1):e86023.
- 390 [40] D'Souza G, Wentz A, Kluz N, Zhang Y, Sugar E, Youngfellow RM, et al. Sex differences in risk factors and
391 natural history of oral human papillomavirus infection. *The Journal of Infectious Diseases*. 2016;213(12):1893-6.
- 392 [41] Chung CH, Bagheri A, D'Souza G. Epidemiology of oral human papillomavirus infection. *Oral oncology*.
393 2014;50(5):364-9.
- 394 [42] Brouwer AF, Eisenberg MC, Carey TE, Meza R. Multisite HPV infections in the United States (NHANES 2003–
395 2014): an overview and synthesis. *Preventive medicine*. 2019;123:288-98.

Table 1: Demographic, behavioral, and medical history characteristics of participants. N is the number of participants answering the question, and n is the number of respondents answering in the affirmative.

	n	%
<u>Age Group (N=102)</u>		
21-29	67	65.7%
30-39	29	28.4%
40-59	6	5.9%
<u>Race/Ethnicity (N=102)</u>		
White	84	82.4%
Multiracial	8	7.8%
Asian	5	4.9%
Black	5	4.9%
<u>Gender (N=102)</u>		
Nonbinary, genderfluid, agender	49	48.0%
Male, transgender male, transmasculine	50	49.0%
Other / Prefer not to label	3	2.9%
<u>Sexual Orientation (N=102)</u>		
Bisexual, pansexual, or omnisexual	44	43.1%
Queer	37	36.3%
Homosexual	9	8.8%
Asexual or demisexual	8	7.8%
Straight or heterosexual	3	2.9%
Other / Prefer not to label	1	1.0%
<u>Highest Level of Education (N=102)</u>		
High school or less	8	7.8%
Some college	27	26.5%
2- or 4- year degree	46	45.1%
Professional or doctorate degree	21	20.6%
<u>Current Employment Status (N=102)</u>		
Full time	38	37.3%
Student	22	21.6%
Part time	15	14.7%
Unemployed, looking for work	12	11.8%
Disabled and not working	10	9.8%
Unemployed, not looking for work	5	4.9%
<u>Yearly Household Income (N=102)</u>		
Less than \$10,000	17	16.8%
\$10,000 - \$19,999	19	18.8%
\$20,000 - \$39,999	20	19.8%
\$40,000 - \$49,999	21	20.8%
\$50,000 +	24	23.8%
<u>Developed Environment (N=102)</u>		

Suburban	49	48.0%
Urban	47	46.1%
Rural	6	5.9%
<u>Marital Status (N=102)</u>		
Single partner, married	47	46.1%
Never married or partnered	25	24.5%
Single partner, never married	12	11.8%
Multiple committed partners	11	10.8%
Separated, divorced, or widowed	7	6.9%
<u>History of sexual behaviors</u>		
Ever engaged in deep kissing (N=102)	98	96.1%
Ever engaged in vaginal/front hole sex (N=97)	95	97.9%
Ever engaged in oral sex (N=96)	95	99.0%
Ever engaged in insertive anal sex (N=95)	57	60.0%
Ever engaged in rimming/anilingus (N=100)	43	43.0%
Ever engaged in mutual masturbation (N=100)	89	89.0%
<u>Gender-affirming transition</u>		
Have transitioned or are transitioning (N=102)	77	75.5%
Ever taken hormones for transition (N=76)	58	76.3%
Ever had surgery for transitions (N=77)	32	41.6%
<u>Substance use (N=100)</u>		
Current alcohol use	75	75.0%
Ever cannabis use	54	54.0%
Current cannabis use	43	43.0%
Ever cigarette use	24	24.0%
Current cigarette use	8	8.0%
Ever used illegal drugs	21	21.0%
Ever illicitly used prescription painkillers	25	25.0%
<u>Medical history</u>		
Ever pregnant (N=102)	14	13.7%
Ever had a cervical Pap test (N=102)	83	81.4%
Ever had an anal Pap test (N=102)	6	5.9%
Ever had HPV (N=102)	8	7.8%
Ever had other STI (N=100)	22	22.0%
At least one dose of HPV vaccine (N=102)	58	56.9%
<u>Medical Insurance</u>		
Private insurance	44	44.4%
Public insurance	32	32.3%
Parents' private insurance	23	23.2%
<u>Ever Delayed Checkups</u>		
Yes, to avoid dysphoria or physical discomfort	61	59.8%
Yes, fear of discrimination	16	15.7%
Yes, provider lacked knowledge of trans-specific care	6	5.9%

No	19	18.6%
<u>Ever Delayed Treatment for Injury or Illness</u>	102	-
Yes, to avoid dysphoria or physical discomfort	37	36.3%
Yes, fear of discrimination	14	13.7%
Yes, provider lacked knowledge of trans-specific care	3	2.9%
No	48	47.1%

Table 2: HPV prevalence and prevalence ratios by site and participant demographic, behavioral, and medical characteristics. Significantly different prevalence ratios are highlighted and bolded. N = number of individuals with valid test results in each group, P = prevalence of HPV within each group, PR = prevalence ratio of HPV in each group compared to referent group, and 95% CI = 95% confidence interval for each prevalence ratio. Bolded values are statistically significant at level of significance $\alpha=0.05$. †Cells with fewer than 5 participants are censored.

	Oral HPV (91 Valid Tests)				Cervicovaginal HPV (82 Valid Tests)				Anal HPV (48 Valid Tests)			
	N	P	PR	95% CI	N	P	PR	95% CI	N	P	PR	95% CI
<u>Total</u>	91	8.8%	-	-	82	30.5%	-	-	48	39.6%	-	-
<u>Age Group</u>	91	-	-	-	82	-	-	-	48	-	-	-
21-29	61	11.5%	1.00	(Ref)	58	32.8%	1.00	(Ref)	34	41.2%	1.00	(Ref)
30-39	25	4.0%	0.35	0.05, 2.69	21	19.1%	0.58	0.22, 1.51	14	35.7%	0.87	0.39, 1.95
40-59	5	0.0%	0.00	-	3	†	†	†	0	-	-	-
<u>Race/Ethnicity</u>	91	-	-	-	82	-	-	-	48	-	-	-
White	73	6.9%	1.00	(Ref)	67	26.9%	1.00	(Ref)	39	38.5%	1.00	(Ref)
Multiracial	8	25.0%	3.65	0.84, 15.9	7	28.6%	1.06	0.31, 3.66	3	†	†	†
Asian	5	0.0%	0.00	-	4	†	†	†	3	†	†	†
Black	5	20.0%	2.92	0.42, 20.5	4	†	†	†	3	†	†	†
<u>Gender</u>	91	-	-	-	82	-	-	-	48	-	-	-
Non-binary, genderfluid, agender	44	4.6%	1.00	(Ref)	37	18.9%	1.00	(Ref)	23	30.4%	1.00	(Ref)
Male, transgender male, transmasculine	44	11.4%	2.50	0.51, 12.2	42	38.1%	2.01	0.93, 4.35	23	47.8%	1.57	0.74, 3.33
<u>Sexual Attraction</u>	91	-	-	-	82	-	-	-	48	-	-	-
Bisexual, pansexual, omnisexual	41	7.8%	1.00	(Ref)	39	33.3%	1.00	(Ref)	21	42.9%	1.00	(Ref)
Queer	31	6.5%	0.66	0.13, 3.38	28	14.3%	0.43	0.16, 1.18	15	26.7%	0.62	0.24, 1.65
Homosexual	9	22.2%	2.28	0.49, 10.59	7	71.4%	2.14	1.12, 4.09	6	83.3%	1.94	1.06, 3.58
Asexual or demisexual	6	0.0%	0.00	-	4	†	†	†	3	†	†	†

Straight or heterosexual	3	†	†	†	3	†	†	†	2	†	†	†
<u>Highest Level of Education</u>	91	-	-	-	82	-	-	-	48	-	-	-
High school or less	8	0.0%	0.00	-	5	60.0%	1.63	0.71, 3.73	5	60.0%	1.58	0.64, 3.87
Some college	24	12.5%	1.31	0.32, 5.38	23	21.7%	0.59	0.24, 1.42	13	38.5%	1.01	0.42, 2.43
2- or 4- year degree	42	9.5%	1.00	(Ref)	38	36.8%	1.00	(Ref)	21	38.1%	1.00	(Ref)
Professional/doctorate degree	17	5.9%	0.62	0.07, 5.13	16	18.8%	0.51	0.17, 1.53	9	33.3%	0.88	0.30, 2.56
<u>Current Employment Status</u>	91	-	-	-	82	-	-	-	48	-	-	-
Full time	35	17.1%	1.00	(Ref)	30	43.3%	1.00	(Ref)	21	42.9%	1.00	(Ref)
Student	19	10.5%	0.61	0.14, 2.75	18	27.8%	0.64	0.27, 1.50	10	30.0%	0.70	0.24, 2.04
Part time	14	0.0%	0.00	-	11	9.1%	0.21	0.03, 1.42	6	33.3%	0.78	0.23, 2.67
Unemployed, looking for work	9	0.0%	0.00	-	9	33.3%	0.77	0.28, 2.11	4	†	†	†
Disabled and not working	10	0.0%	0.00	-	9	22.2%	0.51	0.14, 1.86	5	40.0%	0.93	0.29, 3.04
Unemployed, not looking	4	†	†	†	5	20.0%	0.46	0.08, 2.79	2	†	†	†
<u>Yearly Household Income</u>	90	-	-	-	81	-	-	-	47	-	-	-
Less than \$10,000	16	6.3%	1.00	(Ref)	13	30.8%	1.00	(Ref)	5	60.0%	1.00	(Ref)
\$10,000 - \$19,999	17	5.9%	0.94	0.06, 13.8	16	37.5%	1.22	0.43, 3.42	12	50.0%	0.83	0.33, 2.08
\$20,000 - \$39,999	16	12.5%	2.00	0.20, 19.9	18	50.0%	1.63	0.64, 4.15	11	36.4%	0.61	0.21, 1.75
\$40,000 - \$49,999	18	22.2%	3.56	0.44, 28.6	17	17.7%	0.57	0.15, 2.13	11	25.0%	0.61	0.21, 1.75
\$50,000 +	23	0.0%	0.00	-	17	17.7%	0.57	0.15, 2.13	8	40.4%	0.42	0.10, 1.69
<u>Developed Environment</u>	91	-	-	-	82	-	-	-	48	-	-	-
Suburban	44	9.1%	1.00	(Ref)	35	28.6%	1.00	(Ref)	18	38.9%	1.00	(Ref)
Urban	41	7.3%	0.80	0.19, 3.38	41	29.3%	1.02	0.50, 2.08	28	39.3%	1.01	0.48, 2.12
Rural	6	16.7%	1.83	0.24, 13.8	6	50.0%	1.75	0.67, 4.55	2	50.0%	1.29	0.29, 5.77
<u>Marital Status</u>	91	-	-	-	82	-	-	-	48	-	-	-
Single partner, married	43	14.0%	1.00	(Ref)	39	25.6%	1.00	(Ref)	21	38.1%	1.00	(Ref)
Never married or partnered	25	8.0%	0.57	0.13, 2.63	22	45.5%	1.77	0.88, 3.58	16	43.8%	1.15	0.53, 2.50
Single partner, never married	10	0.0%	0.00	-	8	12.5%	0.49	0.07, 3.29	3	†	†	†
Multiple committed partners	7	0.0%	0.00	-	7	28.6%	1.11	0.31, 4.04	6	33.3%	0.88	0.25, 3.07
Separated/divorced/widowed	6	0.0%	0.00	-	6	33.3%	1.30	0.37, 4.54	2	†	†	†
<u>Partners with a Vagina, Deep Kissing, Last 6 Months</u>	90	-	-	-	80	-	-	-	48	-	-	-
Never	3	†	†	†	1	†	†	†	0	†	†	†
0	40	5.0%	1.00	(Ref)	38	36.8%	1.00	(Ref)	24	50.0%	1.00	(Ref)
1	39	12.8%	2.56	0.53, 12.44	35	20.0%	0.54	0.25, 1.19	18	22.2%	0.44	0.17, 1.15
2 - 4	8	12.5%	2.50	0.26, 24.38	6	66.7%	1.81	0.90, 3.65	6	50.0%	1.00	0.41, 2.45
<u>Partners with a Penis, Deep Kissing, Last 6 Months</u>	90	-	-	-	80	-	-	-	48	-	-	-
Never	5	0.00%	0.00	-	3	†	†	†	1	†	†	†
0	42	11.9%	1.00	(Ref)	39	25.6%	1.00	(Ref)	15	13.3%	1.00	(Ref)
1	32	9.4%	0.79	0.20, 3.05	28	35.7%	1.39	0.67, 2.89	22	50.0%	3.75	0.97, 14.6
2 - 4	5	0.0%	0.00	-	5	20.0%	0.78	0.12, 4.88	5	40.0%	3.00	0.56, 16.1

5 +	6	0.0%	0.00	-	5	80.0%	3.12	1.56, 6.23	5	80.0%	6.00	1.54, 23.4
<u>Partners with a Vagina, Any Sex, Last 6 Months</u>	91	-	-	-	82	-	-	-	48	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	48	6.3%	1.00	(Ref)	45	35.6%	1.00	(Ref)	30	46.7%	1.00	(Ref)
1	33	12.1%	1.94	0.46, 8.10	30	20.0%	0.56	0.25, 1.27	13	23.1%	0.49	0.17, 1.43
2 - 4	5	0.0%	0.00	-	4	†	†	†	4	†	†	†
<u>Partners with a Penis, Any Sex, Last 6 Months</u>	91	-	-	-	82	-	-	-	48	-	-	-
Never	5	0.0%	0.00	-	3	0.0%	0.00	-	1	0.0%	0.00	-
0	46	10.9%	1.00	(Ref)	44	27.3%	1.00	(Ref)	17	17.7%	1.00	(Ref)
1	31	9.7%	0.89	0.23, 3.46	27	33.3%	1.22	0.59, 2.51	22	50.0%	2.83	0.94, 8.6
2 - 4	6	0.0%	0.00	-	5	20.0%	0.73	0.12, 4.52	5	40.0%	2.27	0.51, 10.0
5 +	3	†	†	†	3	†	†	†	3	†	†	†
<u>Partners with a Vagina, Vaginal/Front Hole Sex, Last 6 Months</u>	89	-	-	-	81	-	-	-	46	-	-	-
Never	5	0.0%	0.00	-	3	0.0%	0.00	-	1	0.0%	0.00	-
0	43	4.7%	1.00	(Ref)	41	34.2%	1.00	(Ref)	27	48.2%	1.00	(Ref)
1	37	13.5%	2.91	0.60, 14.10	33	21.2%	0.62	0.28, 1.36	15	20.0%	0.42	0.14, 1.23
2 - 4	4	†	†	†	4	†	†	†	3	†	†	†
<u>Partners with a Penis, Vaginal/Front Hole Sex, Last 6 Months</u>	89	-	-	-	81	-	-	-	46	-	-	-
Never	5	0.0%	0.00	-	3	0.0%	0.00	-	1	0.0%	0.00	-
0	47	8.5%	1.00	(Ref)	45	24.4%	1.00	(Ref)	18	16.7%	1.00	(Ref)
1	26	11.5%	1.36	0.33, 5.60	23	39.1%	1.60	0.78, 3.30	18	44.4%	2.67	0.84, 8.46
2 - 4	8	0.0%	0.00	-	7	14.3%	0.58	0.09, 3.85	6	50.0%	3.00	0.81, 11.1
5 +	3	†	†	†	3	†	†	†	3	†	†	†
<u>Partners with a Vagina, Participant Receiving Oral Sex, Last 6 Months</u>	48	-	-	-	44	-	-	-	23	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	11	9.1%	0.59	0.07, 4.71	10	0.0%	0.00	-	6	16.7%	0.92	0.10, 8.15
1	26	15.4%	1.00	(Ref)	26	23.1%	1.00	(Ref)	11	18.2%	1.00	(Ref)
2 - 4	6	16.7%	1.08	0.15, 8.03	5	80.0%	3.47	1.52, 7.93	5	60.0%	3.30	0.78, 20.0
<u>Partners with a Penis, Participant Receiving Oral Sex, Last 6 Months</u>	41	-	-	-	36	-	-	-	29	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	3	†	†	†	3	†	†	†	1	†	†	†
1	25	8.0%	1.00	(Ref)	22	27.3%	1.00	(Ref)	19	42.1%	1.00	(Ref)
2 - 4	5	0.0%	0.00	-	5	20.0%	0.73	0.11, 4.81	5	60.0%	1.43	0.59, 3.47
5 +	3	†	†	†	3	†	†	†	3	†	†	†

<u>Partners with a Vagina, Participant Performing Oral Sex, Last 6 Months</u>	48	-	-	-	44	-	-	-	23	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	8	0.0%	0.00	-	8	0.0%	0.00	-	4	†	†	†
1	30	16.7%	1.00	(Ref)	29	24.1%	1.00	(Ref)	14	28.6%	1.00	(Ref)
2 - 4	5	20.0%	1.20	0.17, 8.24	4	†	†	†	4	†	†	†
<u>Partners with a Penis, Participant Performing Oral Sex, Last 6 Months</u>	41	-	-	-	36	-	-	-	29	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	1	†	†	†	0	†	†	†	0	†	†	†
1	27	11.1%	1.00	(Ref)	25	36.0%	1.00	(Ref)	20	45.0%	1.00	(Ref)
2 - 4	5	0.0%	0.00	-	5	20.0%	0.56	0.09, 3.46	5	60.0%	1.33	0.56, 3.16
5 +	3	†	†	†	3	†	†	†	3	†	†	†
<u>Partners with a Vagina, Anal Sex, Last 6 Months</u>	56	-	-	-	51	-	-	-	32	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	39	7.7%	1.00	(Ref)	36	30.6%	1.00	(Ref)	27	40.7%	1.00	(Ref)
1	12	8.3%	1.08	0.12, 9.48	12	33.3%	1.09	0.43, 2.79	4	25.0%	0.61	0.11, 3.56
<u>Partners with a Penis, Anal Sex, Last 6 Months</u>	56	-	-	-	51	-	-	-	32	-	-	-
Never	5	0.0%	0.00	-	3	†	†	†	1	†	†	†
0	35	5.7%	1.00	(Ref)	35	28.6%	1.00	(Ref)	20	30.0%	1.00	(Ref)
1	14	14.3%	2.50	0.39, 16.05	11	45.5%	1.59	0.69, 3.66	9	55.6%	1.85	0.76, 4.50
2 - 4	2	†	†	†	2	†	†	†	2	†	†	†
<u>Transitioned/Transitioning</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes	69	7.3%	1.00	(Ref)	66	31.8%	1.00	(Ref)	36	41.7%	1.00	(Ref)
No	22	13.6%	1.88	0.49, 7.25	16	25.0%	0.79	0.31, 1.97	12	33.3%	0.80	0.33, 1.95
<u>Ever Taken Hormones for Gender-Affirming Treatment</u>	68	-	-	-	65	-	-	-	36	-	-	-
Yes	50	8.0%	1.00	(Ref)	51	33.3%	1.00	(Ref)	29	44.8%	1.00	(Ref)
No	18	5.6%	0.69	0.08, 5.81	14	21.4%	0.64	0.22, 1.88	7	28.6%	0.64	0.18, 2.20
<u>Ever Had Gender-Affirming Surgery</u>	69	-	-	-	66	-	-	-	36	-	-	-
Yes	28	7.1%	0.98	0.17, 5.47	28	35.7%	1.23	0.61, 2.49	16	50.0%	1.43	0.66, 3.09
No	41	7.3%	1.00	(Ref)	38	29.0%	1.00	(Ref)	20	35.0%	1.00	(Ref)
<u>Ever Been Pregnant</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes	13	0.0%	0.00	-	9	33.3%	1.11	0.41, 2.97	6	16.7%	0.39	0.06, 2.41
No	78	10.3%	1.00	(Ref)	73	30.1%	1.00	(Ref)	42	42.9%	1.00	(Ref)
<u>Alcohol Use</u>	89	-	-	-	80	-	-	-	47	-	-	-
Current	66	10.6%	1.00	(Ref)	61	27.9%	1.00	(Ref)	35	37.1%	1.00	(Ref)
Non-current	23	4.4%	0.41	0.05, 3.15	19	36.8%	1.32	0.65, 2.70	12	41.7%	1.12	0.51, 2.49
<u>Marijuana Use</u>	89	-	-	-	80	-	-	-	47	-	-	-

Ever	46	17.4%	1.00	(Ref)	48	33.3%	1.00	(Ref)	28	46.4%	1.00	(Ref)
Never	43	0.0%	0.00	-	32	25.0%	0.75	0.36, 1.54	19	26.3%	0.57	0.24, 1.33
<u>Smoking Status</u>	89	-	-	-	80	-	-	-	47	-	-	-
Never	62	9.7%	1.00	(Ref)	56	28.6%	1.00	(Ref)	31	38.7%	1.00	(Ref)
Previous	21	9.5%	0.98	0.21, 4.51	20	25.0%	0.88	0.37, 2.08	12	25.0%	0.65	0.22, 1.89
Current	6	0.0%	0.00	-	4	†	†	†	4	†	†	†
<u>HPV Vaccination</u>	91	-	-	-	82	-	-	-	48	-	-	-
At least one dose	53	9.4%	1.00	(Ref)	52	30.8%	1.00	(Ref)	27	29.6%	1.00	(Ref)
None	38	7.9%	0.84	0.21, 3.29	30	30.0%	0.98	0.49, 1.93	21	52.4%	1.77	0.87, 3.60
<u>Ever Had a Cervical Pap Smear</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes	74	9.5%	1.00	(Ref)	66	31.8%	1.00	(Ref)	39	43.6%	1.00	(Ref)
No	17	5.9%	0.62	0.08, 4.72	16	25.0%	0.79	0.31, 1.97	7	22.2%	0.51	0.14, 1.82
<u>Ever Had an Anal Pap Smear</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes	6	16.7%	2.02	0.30, 13.87	4	†	†	†	4	†	†	†
No	85	8.2%	1.00	(Ref)	78	28.2%	1.00	(Ref)	44	34.1%	1.00	(Ref)
<u>History of HPV</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes	8	0.0%	0.00	-	7	71.4%	2.68	1.47, 4.88	5	60.0%	1.61	0.71, 3.64
No	83	9.6%	1.00	(Ref)	75	26.7%	1.00	(Ref)	43	37.2%	1.00	(Ref)
<u>History of other STI</u>	89	-	-	-	82	-	-	-	47	-	-	-
Yes	20	5.0%	0.58	0.07, 4.50	20	50.0%	2.07	1.11, 3.85	15	66.7%	2.67	1.33, 5.36
No	69	8.7%	1.00	(Ref)	62	24.2%	1.00	(Ref)	32	25.0%	1.00	(Ref)
<u>Medical Insurance</u>	89	-	-	-	80	-	-	-	48	-	-	-
Private insurance	39	10.3%	1.00	(Ref)	33	30.3%	1.00	(Ref)	19	36.8%	1.00	(Ref)
Public insurance	28	7.1%	0.70	0.14, 3.54	27	33.3%	1.10	0.52, 2.31	18	55.6%	1.51	0.73, 3.10
Parents' private insurance	22	9.1%	0.89	0.18, 4.46	20	30.0%	0.99	0.42, 2.31	11	18.2%	0.49	0.12, 1.97
<u>Ever Delayed Checkups</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes, to avoid dysphoria or physical discomfort	53	7.6%	1.00	(Ref)	51	29.4%	1.00	(Ref)	28	53.6%	1.00	(Ref)
Yes, fear of discrimination	15	6.7%	0.88	0.11, 7.32	12	41.7%	1.42	0.64, 3.13	6	0.0%	0.00	-
Yes, provider lacked knowledge of trans-specific care	5	0.0%	0.00	-	5	20.0%	0.68	0.11, 4.13	4	†	†	†
No	18	16.7%	2.21	0.55, 8.94	14	28.6%	0.97	0.38, 2.47	10	30.0%	0.56	0.20, 1.53
<u>Ever Delayed Treatment for Injury or Illness</u>	91	-	-	-	82	-	-	-	48	-	-	-
Yes, to avoid dysphoria or physical discomfort	32	3.1%	0.23	0.03, 1.81	30	33.3%	1.30	0.62, 2.71	16	56.3%	1.85	0.87, 3.93
Yes, fear of discrimination	12	8.3%	0.61	0.08, 4.60	10	50.0%	1.95	0.86, 4.42	8	25.0%	0.82	0.21, 3.93
Yes, provider lacked knowledge of trans-specific care	3	†	†	†	3	†	†	†	1	†	†	†
No	44	13.6%	1.00	(Ref)	39	25.6%	1.00	(Ref)	23	30.4%	1.00	(Ref)

Supporting Information

Table S1: Demographic, behavioral, and medical history characteristics of participants. N is the number of participants answering the question, and n is the number of respondents answering in the affirmative.

	n	%
<u>Partners with a Vagina, Deep Kissing, Last 6 Months</u>	99	-
Never	3	3.0%
0	44	44.4%
1	43	43.4%
2 - 4	9	9.1%
5 +	0	0.0%
<u>Partners with a Penis, Deep Kissing, Last 6 Months</u>	99	-
Never	5	5.1%
0	49	49.5%
1	33	33.3%
2 - 4	6	6.1%
5 +	6	6.1%
<u>Partners with a Vagina, Vaginal / Oral / Anal Sex, Last 6 Months</u>	102	-
Never	5	4.9%
0	53	52.0%
1	38	37.3%
2 - 4	6	5.9%
5 +	0	0.0%
<u>Partners with a Penis, Vaginal / Oral / Anal Sex, Last 6 Months</u>	102	-
Never	5	4.9%
0	54	52.9%
1	33	32.4%
2 - 4	7	6.9%
5 +	3	2.9%
<u>Partners with a Vagina, Vaginal / Front Hole Sex, Last 6 Months</u>	100	-
Never	5	5.0%
0	49	49.0%
1	41	41.0%
2 - 4	5	5.0%
5 +	0	0.0%
<u>Partners with a Penis, Vaginal / Front Hole Sex, Last 6 Months</u>	100	-
Never	5	5.0%
0	55	55.0%
1	28	28.0%
2 - 4	9	9.0%
5 +	3	3.0%
<u>Partners with a Vagina, Participant Receiving Oral Sex, Last 6</u>	55	-

<u>Months</u>		
Never	5	9.1%
0	12	21.8%
1	31	56.6%
2 - 4	7	12.7%
5 +	0	0.0%
<u>Partners with a Penis, Participant Receiving Oral Sex, Last 6</u>	44	-
<u>Months</u>		
Never	5	11.4%
0	3	6.8%
1	28	63.6%
2 - 4	5	11.4%
5 +	3	6.8%
<u>Partners with a Vagina, Participant Performing Oral Sex, Last 6</u>	55	-
<u>Months</u>		
Never	5	9.1%
0	10	18.2%
1	34	61.8%
2 - 4	6	10.9%
5 +	0	0.0%
<u>Partners with a Penis, Participant Performing Oral Sex, Last 6</u>	44	-
<u>Months</u>		
Never	5	11.4%
0	2	4.6%
1	28	63.6%
2 - 4	6	13.6%
5 +	3	6.8%
<u>Partners with a Vagina, Anal Sex, Last 6 Months</u>	62	-
Never	5	8.1%
0	43	69.4%
1	14	22.6%
2 - 4	0	0.0%
5 +	0	0.0%
<u>Partners with a Penis, Anal Sex, Last 6 Months</u>	62	-
Never	5	8.1%
0	40	64.5%
1	14	22.6%
2 - 4	3	4.8%
5 +	0	0.0%

Table S2. Prevalence of HPV genotypes in each sample type, and number and percentage of anal/ cervicovaginal and oral/ cervicovaginal matches.

HPV Genotype	Oral (91 Valid Tests)		Cervicovaginal (82 Valid Tests)		Anal (48 Valid Tests)	
	Number Positive	%	Number Positive	%	Number Positive	%
Any	8	8.8%	25	30.5%	16	33.3%
HPV 6	0	0.0%	2	2.4%	1	2.1%
HPV 11	0	0.0%	0	0.0%	0	0.0%
HPV 16	1	1.1%	3	3.7%	3	6.3%
HPV 18	2	2.2%	5	6.1%	1	2.1%
HPV 31	0	0.0%	0	0.0%	0	0.0%
HPV 33	0	0.0%	0	0.0%	1	2.1%
HPV 35	0	0.0%	0	0.0%	1	2.1%
HPV 39	1	1.1%	3	3.7%	3	6.3%
HPV 45	0	0.0%	1	1.2%	0	0.0%
HPV 51	1	1.1%	6	7.3%	4	8.3%
HPV 52	0	0.0%	4	4.9%	1	2.1%
HPV 56	1	1.1%	5	6.1%	3	6.3%
HPV 58	0	0.0%	1	1.2%	0	0.0%
HPV 59	0	0.0%	5	6.1%	1	2.1%
HPV 66	2	2.2%	3	3.7%	3	6.3%
HPV 68	0	0.0%	3	3.7%	0	0.0%
HPV 73	0	0.0%	2	2.4%	0	0.0%
HPV 90	0	0.0%	1	1.2%	1	2.1%
COBAS Test (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)	8	8.8%	23	28.1%	15	31.3%
IARC Group 1 (Carcinogenic) (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59)	6	6.6%	22	26.8%	13	27.1%
Included in Gardasil (HPV 6, 11, 16, and 18)	3	3.3%	10	12.2%	5	10.4%
Included in Gardasil 9 (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58)	3	3.3%	14	17.1%	6	12.5%
Cause Genital Warts (HPV 6 and 11)	0	0.0%	2	2.4%	1	2.1%

Table S3. Genotype concordance between anal and cervicovaginal and between oral and cervicovaginal HPV infections.

HPV Genotype	Anal/cervicovaginal genotype matches (44 participants with valid tests for both samples)			Oral/cervicovaginal genotype matches (75 participants with valid tests for both samples)		
	Number positive for both	% of positive cervicovaginal tests	% of positive anal Tests	Number positive for both	% of positive cervicovaginal tests	% of positive oral tests
Any	11	34.4%	50.0%	5	12.2%	71.4%
HPV 6	1	50.0%	100.0%	0	0.0%	-
HPV 11	0	-	-	0	-	-
HPV 16	1	33.3%	33.3%	0	0.0%	0.0%
HPV 18	0	0.0%	0.0%	1	25.0%	50.0%
HPV 31	0	-	-	0	-	-
HPV 33	0	-	0.0%	0	-	-
HPV 35	0	-	0.0%	0	-	-
HPV 39	2	100.0%	66.7%	0	0.0%	-
HPV 45	0	0.0%	-	0	0.0%	-
HPV 51	1	33.3%	25.0%	1	16.7%	100.0%
HPV 52	1	25.0%	100.0%	0	0.0%	-
HPV 56	2	50.0%	66.7%	1	20.0%	100.0%
HPV 58	0	0.0%	-	0	0.0%	-
HPV 59	1	25.0%	100.0%	0	0.0%	-
HPV 66	1	100.0%	50.0%	2	66.7%	100.0%
HPV 68	0	0.0%	-	0	0.0%	-
HPV 73	0	0.0%	-	0	0.0%	-
HPV 90	1	100.0%	100.0%	0	0.0%	-